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UrineUrinary biomarkers of oxidative stress have been little studied in adults with Down syndrome (DS), usually no
more than two biomarkers have been measured in the population studied and controversial results are
reported in literature. Thus, we aimed to assess a set of oxidative and nitrosative stress biomarkers in urine
samples of adolescents and adults with DS, with andwithout hypothyroidism, which comprise: 8-hydroxy-2′-
deoxyguanosine (8-OHdG), isoprostane 15-F2t-IsoP, thiobarbituric acid-reacting substances (TBARS),
advanced glycation end products (AGEs), dityrosine (diTyr), hydrogen peroxide (H2O2) and nitrite/nitrate
(NOx). Fluorimetric and spectrophotometric assays were performed in DS (n=78), some of them taking
levothyroxine for hypothyroidism (n=24), and in their healthy age-matched controls (n=65). We found
that levels of AGEs, diTyr, H2O2 and NOx are increased in DS patients in any or in all age groups, whereas Cr
levels were lower in DS than in controls in all age groups. Besides, correlations with age in DSwere positive for
diTyr and negative for Cr, TBARS, 15-F2t-IsoP and NOx. We also found lower levels of Cr from 15 to 19 years,
higher levels of TBARS and AGEs from 20 to 40 years and higher levels of diTyr from 15 to 40 years in DS
patients receiving levothyroxine than in DS without hypothyroidism diagnosed. We conclude that AGEs,
diTyr, H2O2 and NOx could be used as oxidative stress biomarkers in DS in contrast to 8-OHdG, 15-F2t-IsoP and
TBARS, at least with the methods used. However, renal impairment could occur in DS and Cr adjustment may
bias the results, particularly in hypothyroid patients.ine; 15-F2t-IsoP, isoprostane;
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Down syndrome (DS), caused by the triplication of chromosome
21 (HSA21) or part of it, is found to be one of the more complex
genetic conditions compatible with a large survival. However,
individuals with DS suffer from accelerate aging, being DS considered
as a progeroid syndrome, which may be the result of an increased
oxidative stress observed in these patients. The trisomy, affecting
more than 300 genes, is associated with a variety of manifestations,
including pathologies which are possibly related to aging such as
Alzheimer disease, cataracts, leukemia, diabetes mellitus, hypogonad-ism, vascular disease, amyloidosis and premature graying or loss of
hair.
The amount of studies reporting a number of dysfunctions
associating oxidative stress with DS phenotype is increasing. An excess
of the enzyme Cu/Zn superoxide dismutase (SOD1) activity has been
considered as the main responsible for the increased oxidative stress
found in patients with DS [1]. Besides, several abnormalities in
mitochondrial function have been found in DS and also in mouse
models of this pathology. Indeed, in addition to SOD1, there are at least
15 genes or predicted genes on HSA21 with a role in mitochondrial
energy generation and reactive oxygen species metabolism [2].
There are considerable studies providing evidence about the free
radical involvement in the pathogenesis of DS based on biomarkers of
oxidative stress measurements [3–5], which are stable adducts that
are produced as a result of the oxidative processes in vivo. However,
urinary biomarkers of oxidative stress have been little studied in this
condition, the set of markers measured in each work is very limited
and studies are normally performed in a reduced age range. In fact,
most works are performed only in children, being the biomarkers of
oxidative stress poorly studied in DS adults or in the elderly stage.
The use of urine samples provides many advantages over plasma
or serum in population studies as their collection does not require any
invasive technique. Since it is particularly difﬁcult to obtain reliable
24 h urine samples and sampling is often incomplete (whichmay bias
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high. Moreover, urine is the preferred body ﬂuid for the measurement
of isoprostanes [6]. For all these reasons, we chose urine as the
specimen of choice in this study.
In order to assess the reliability of a set of urinary biomarkers of
oxidative and nitrosative stress in DS, we studied the urinary levels of:
8-hydroxy-2′-deoxyguanosine (8-OHdG), isoprostane 15-F2t-IsoP
(also 8-epi-PGF2α, 8-iso-PGF2α or iPF2α-III), thiobarbituric acid-
reacting substances (TBARS), advanced glycation end products
(AGEs), dityrosine (diTyr), hydrogen peroxide (H2O2) and nitrite/
nitrate (NOx) in a sample of adolescents, adults and senescent
subjects with DS and in those of healthy age-matched controls.
Moreover, we compare these parameters in DS treated with
levothyroxine with DS without thyroid dysfunction diagnosed to
ﬁnd out whether hypothyroidism is related to oxidative stress in DS.2. Materials and methods
2.1. Subjects
The study was performed in 78 patients with DS and 65 healthy
controls. Clinical characteristics of participants are shown in Table 1.
Three age groups were established: from 15 to 19 years (age group 1),
from 20 to 40 years (age group 2) and N40 years (age group 3). These
groups represent respectively: early adulthood, adulthood and senes-
cence (based on DS individuals according to the classiﬁcation of Bittles
et al. [7]). Participants ﬁlled in a comprehensive questionnaire to obtain
the following information: a) sociodemographic parameters: age and
gender; b) use of drugs or dietary supplements; c) exercise habits; and
d) smoking habits. All of them were non-smokers and received no
dietary or medicinal vitamin supplementation. Subjects were not
affected by diabetes mellitus, myeloproliferative disorders, any type of
dementia such as Alzheimer disease, malnutrition or treated with drug
possibly interfering with oxidative metabolism, being 24 subjects with
DS taking levothyroxine (synthetic T4 hormone) for hypothyroidism
treatment. Informed consentwas obtained from the participants or was
given by parents. The study was approved by The Ethics Committee of
the Spanish National Research Council.2.2. Urine sample collection and preparation
First morning urine samples on an empty stomach were collected in
a sterile ﬂask covered with aluminium foil to keep out stray light and
processedwithin 2 h of the collection. Sampleswere 1 mLaliquoted and
frozen at −80 °C until analysis. Creatinine (Cr) determination was
performed the day of collection, without previous freezing of the
sample.Table 1
Clinical characteristics of patients.
Controls Down syndrome
Agea
All ages (15–59 years) 32.1±13.1, n=65 28.8±12.4, n=78
Age group 1 (15–19 years) 17.3±1.5, n=15 17.0±1.4, n=29
Age group 2 (20–40 years) 28.7±5.4, n=31 29.6±5.9, n=33
Age group 3 (41–59 years) 49.5±6.5, n=19 48.5±4.6, n=16
Sex (male/female) 26/39 35/43
Hypothyroidism 0 24
Karyotype
Primary trisomy 72
Robertsonian translocation
trisomy der(14;21)(q10;q10)
5
Mosaicism (normal cellular line 94%) 1
a Data are mean±SD and number of subjects (n).2.3. Biochemical determinations
2.3.1. Creatinine (Cr)
Cr was determined according to the spectrophotometric Jaffé
method [8] which is based on the reaction of Cr with picric acid in
alkaline pH, described by Varley et al. [9].
2.3.2. 8-Hydroxy-2′-deoxyguanosine (8-OHdG)
Urinary 8-OHdG was determined by a competitive enzyme-linked
immunosorbent assay (ELISA) kit from the Japan Institute for the
Control of Aging (JaICA, Shizuoka, Japan) according to the manufac-
turer's instruction. Opaque samples were centrifuged at 4000×g for
10 min. Incubations at 37 °C and absorbance measurements were
carried out using a microplate reader (ELx808, Bio-Tek Instruments,
Winooski, VT, USA).
2.3.3. Urinary isoprostane (15-F2t-IsoP)
Free isoprostane 15-F2t-IsoP was analyzed using a commercially
ELISA kit (Oxford Biomedical Research, Oxford, MI, USA). The
procedure was performed following the manufacturer's instruction.
Urine samples were diluted 1:4 in the buffer supplied and a
microplate reader (ELx808, Bio-Tek Instruments, Winooski, VT, USA)
with a 450 nm ﬁlter was used for spectrophotometric measurements.
2.3.4. Thiobarbituric acid-reacting substances (TBARS)
TBARS were measured by the method of Uchiyama and Mihara
[10] with modiﬁcations. Brieﬂy, 33 μL of 0.01% BHT (in absolute
ethanol), 1 mL of 1% phosphoric acid and 300 μL of 42 mmol/L TBA
(dissolved in water and heating) were added to 140 μL of urine,
mixing in vortex. The mixtures were incubated in boiling water for
45 min and, after cooling tubes on ice, 1.4 mL of 1-butanol was added
in each tube. Following a 15 min centrifugation (2000×g), the
absorbance of supernatant was read at 535 nm using a UVmini-
1240 Shimadzu spectrophotometer (Shimadzu, Tokyo, Japan). The
standard absorption curve of MDA was prepared by dissolving it in
phosphate buffer (20 mmol/L, pH 7.0).
2.3.5. Advanced glycation end-products (AGEs)
AGEs was estimated essentially as described by Yanagisawa et al.
[11]. Fluorescence intensity of urine diluted 20-fold in phosphate
buffered saline was measured at 440 nm after excitation at 370 nm,
using a Varioskan Flash microplate reader (Thermo Fisher Scientiﬁc,
Waltham, MA, USA) operating at room temperature. Results were
reported as arbitrary ﬂuorescence units (AFU).
2.3.6. Dityrosine (diTyr)
For diTyr measurement the assay was performed essentially as
described by Witko-Sarsat et al. [12]. In brief, urine was diluted 20-
fold in 50 mmol/L phosphate buffer, pH 7.4, containing 6 mol/L urea.
Fluorescence intensity was measured at excitation and emission
wavelengths of 315 and 410 nm respectively, using a Varioskan Flash
microplate reader (Thermo Fisher Scientiﬁc, Waltham, MA, USA)
operating at room temperature, after 30 min at room temperature.
Results were reported as AFU.
2.3.7. Hydrogen peroxide (H2O2)
H2O2 wasmeasured using the ferrous ion oxidation xylenol orange
version-2 (FOX-2) method of Banerjee et al. [13]. In brief, 90 μL of
urine was mixed with 10 μL of methanol and 900 μL of FOX-2 reagent
(100 μmol/L xylenol orange, 250 μmol/L ammonium ferrous sulfate,
90% methanol, 4 mmol/L BHT and 25 mmol/L sulfuric acid). Tubes
were vortexed and kept at room temperature for 30 min. Following a
10 min centrifugation (15,000×g) absorbance of supernatant was
read at 560 nm against a methanol blank using a UVmini-1240
Shimadzu spectrophotometer (Shimadzu, Tokyo, Japan). Then, the
same procedure was followed except for 10 μL of methanol that were
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phosphate buffer, pH 7.0). Urinary H2O2 concentrations were
calculated from the absorbance difference (with and without
catalase) at 560 nm using a standard curve prepared with H2O2.
2.3.8. Total nitrate and nitrite (NOx)
Total nitrate and nitrite concentration (NOx) was measured by the
acidic Griess reaction according to the method of Miranda et al. [14].
In brief, 100 μL of sample was applied to a microplate well. Following
the addition of 100 μL VCl3 (8 mg/mL in 1 mol/L HCl) to each well
100 μL of the Griess reagent (premixed 50 μL sulfanilamide (2% in 5%
HCl) and 50 μL N-(1-Naphthyl) ethylendiamine dihydrochloride
(0.1%)) were added immediately. Microplate was then incubated at
37 °C for 30 min and absorbance was read at 540 nm using a
microplate reader (ELx808, Bio-Tek Instruments, Winooski, VT,
USA). Nitrate was determined from a linear standard curve estab-
lished with sodium nitrate. Nitrite was measured in a similar mannerTable 2
Urinary levels of Cr and biomarkers of oxidative and nitrosative stress (8-OHdG, 15-F2t-Iso
age-matched controls. The data are expressed as mean±standard deviation (SD) and ran
Urinary biomarker Controls
n Mean±SD Range
Cr (mg/dL)
All ages (15–59 years) 65 193±79 37–470
Age group 1 (15–19 years) 15 198±63 92–334
Age group 2 (20–40 years) 31 206±86 91–470
Age group 3 (N40 years) 19 169±78 37–308
8-OHdG (ng/mg Cr)
All ages (15–59 years) 45 8.3±3.5 2.1–17.7
Age group 1 (15–19 years) 10 8.4±2.2 4.6–12.8
Age group 2 (20–40 years) 23 8.8±4.1 2.1–17.7
Age group 3 (N40 years) 12 7.2±3.1 4.3–15.4
15-F2t-IsoP (ng/mg Cr)
All ages (15–59 years) 44 0.93±0.44 0.21–2.18
Age group 1 (15–19 years) 10 0.78±0.48 0.28–1.46
Age group 2 (20–40 years) 21 1.00±0.40 0.21–1.88
Age group 3 (N40 years) 13 0.98±0.46 0.41–2.18
TBARS (μg/mg Cr)
All ages (15–59 years) 65 0.77±0.32 0.00–1.71
Age group 1 (15–19 years) 15 0.85±0.37 0.46–1.71
Age group 2 (20–40 years) 31 0.70±0.26 0.30–1.37
Age group 3 (N40 years) 19 0.80±0.35 0.00–1.59
AGEs (AFU/mg Cr)
All ages (15–59 years) 61 134±47 76–359
Age group 1 (15–19 years) 14 118±33 76–188
Age group 2 (20–40 years) 30 123±25 81–175
Age group 3 (N40 years) 17 166±68‡ 105–359
DiTyr (AFU/mg Cr)
All ages (15–59 years) 61 494±149 249–1200
Age group 1 (15–19 years) 14 512±133 258–731
Age group 2 (20–40 years) 30 450±106 302–659
Age group 3 (N40 years) 17 559±205 249–1200
H2O2 (μg/mg Cr)
All ages (15–59 years) 58 0.39±0.40 0.00–1.71
Age group 1 (15–19 years) 14 0.59±0.55 0.09–1.71
Age group 2 (20–40 years) 29 0.33±0.31 0.05–1.56
Age group 3 (N40 years) 15 0.33±0.35 0.00–1.20
NOx (μg/mg Cr)
All ages (15–59 years) 64 46±34 14–186
Age group 1 (15–19 years) 15 50±36 21–158
Age group 2 (20–40 years) 31 38±24 14–121
Age group 3 (N40 years) 18 58±45 16–186
†,‡Indicate Pb0.05 (signiﬁcantly different) from the age group 1 and the age group 2, respe
*Pb0.05, **Pb0.01 and ***Pb0.001 (signiﬁcantly different) from the control group.
a By Mann–Whitney U-test.
b By Student's unpaired t-test.except for the fact that samples and nitrite standards were only
exposed to Griess reagent.
2.4. Statistical analysis
Data are presented as mean±standard deviation (SD) and range.
Normal distribution and homogeneity of variance of the data were
tested by the Shapiro–Wilk's and Levene's tests, respectively. For
parametric variables Student's unpaired t-test was used whereas
Mann–Whitney U-test was used for nonparametric data. Comparisons
between age groups in both DS and control groups were performed by
one-way analysis of variance (ANOVA) and Scheffé post-hoc test.
Correlation analyses were performed using Pearson's or Spearman's
correlation tests when appropriate and then linear regression
analyses were carried out. Statistical signiﬁcance was set at Pb0.05.
Data were processed using IBM SPSS Statistics 18.0 software (SPSS
Inc., Chicago, IL, USA).P, TBARS, AGEs, diTyr, H2O2 and NOx) in patients with Down syndrome (DS) and their
ges.
DS P
n Mean±SD Range
78 127±63*** 25–298 b0.001a
29 119±55*** 25–276 b0.001b
33 140±65** 34–298 0.001b
16 115±72* 27–290 0.045b
77 8.9±3.5 2.1–24.5 0.181a
29 9.2±3.2 4.9–19.0 0.623a
33 8.8±3.9 2.8–24.5 0.809a
15 8.3±2.9 2.1–12.7 0.152a
78 0.94±0.57 0.19–2.98 0.924b
29 1.14±0.65 0.26–2.98 0.127a
33 0.93±0.49 0.19–2.35 0.608b
16 0.57±0.39*,†,‡ 0.22–1.61 0.016b
78 0.73±0.35 0.00–2.36 0.457a
29 0.81±0.41 0.14–2.36 0.990a
33 0.72±0.26 0.00–1.41 0.861b
16 0.60±0.36* 0.08–1.58 0.029a
75 150±53 64–324 0.063a
29 143±38* 64–234 0.034a
31 143±51 86–276 0.215a
15 178±73 99–324 0.653a
75 794±526*** 165–3877 b0.001a
29 816±479** 165–2473 0.004a
31 745±630*** 259–3877 b0.001a
15 850±377** 349–1858 0.012a
72 0.74±0.69*** 0.00–3.14 b0.001a
29 0.91±0.71 0.22–3.14 0.042a
31 0.51±0.41 0.00–1.39 0.046a
12 0.89±1.03 0.01–2.78 0.152a
74 81±79*** 18–503 b0.001a
29 121±112** 28–503 0.001a
31 55±27**,† 18–116 0.005a
14 58±26† 26–119 0.377a
ctively.
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In the present study, a set of urinary biomarkers of oxidative and
nitrosative stress in a sample of adolescents, adults and senescent
subjects with DS, which comprise: 8-OHdG, 15-F2t-IsoP, TBARS, AGEs,
diTyr, H2O2 and NOx, has been analyzed. Clinical characteristics of DS
and control subjects are summarized in Table 1. No signiﬁcant
differences in age were observed between patients with DS and
controls for any age group (P=0.369 for age group 1, P=0.623 for age
group 2, P=0.678 for age group 3 and P=0.117 for all ages). When
the inﬂuence of gender was analyzed in DS and control groups, no
signiﬁcant differences were found for any parameter in any age group
(PN0.05 for all). Besides, when subjects with Rb translocation or
mosaicism were excluded similar results were obtained.
In Table 2 are listed the urinary levels of Cr, 8-OHdG, 15-F2t-IsoP,
TBARS, AGEs, diTyr, H2O2 and NOx in patients with DS and controls for
all age groups. Table 3 and Fig. 1 show correlations between these
variables and age.
3.1. 8-OHdG
8-OHdG is the most commonly used biomarker of oxidative DNA
damage. We did not ﬁnd differences in urinary levels of 8-OHdG
between DS and controls for any age group (Table 2). These results
agree with those obtained by Pallardó et al. [15] and Seidl et al. [16],
studying 8-OHdG levels in leukocytes and in the cerebral cortex
respectively. They found no signiﬁcant differences between adults
with DS and controls in accordance with our results. Moreover, we
found no correlation with age neither in DS nor in controls (Table 4
and Fig. 1) as it has been reported in previous works using the ELISA
assay of JaICA [17]. However, Jovanovic et al. [1] analyzed 8-OHdG byTable 3
Correlations between age and biochemical parameters in Down syndrome (DS) and
their age-matched controls.
Controls DS
Correlated variables with age r P r P
Cr
All ages (14–59 years) −0.207 0.098a −0.093 0.418a
Age groups 2 and 3 (20–59 years) −0.265 0.063a −0.300 0.036a
8-OHdG
All ages (14–59 years) −0.204 0.179b −0.050 0.667b
Age groups 2 and 3 (20–59 years) −0.211 0.223b −0.021 0.886b
15-F2t-IsoP
All ages (14–59 years) 0.147 0.342a −0.328 0.003a
Age groups 2 and 3 (20–59 years) −0.053 0.766a −0.295 0.040a
TBARS
All ages (14–59 years) 0.113 0.368b −0.287 0.011b
Age groups 2 and 3 (20–59 years) 0.286 0.044b −0.242 0.044b
AGEs
All ages (14–59 years) 0.297 0.021b 0.114 0.339b
Age groups 2 and 3 (20–59 years) 0.326 0.025b 0.252 0.094b
DiTyr
All ages (14–59 years) 0.106 0.420b 0.063 0.594b
Age groups 2 and 3 (20–59 years) 0.364 0.013b 0.375 0.010b
H2O2
All ages (14–59 years) −0.175 0.190b −0.165 0.167b
Age groups 2 and 3 (20–59 years) 0.016 0.918b 0.239 0.123b
NOx
All ages (14–59 years) 0.127 0.318b −0.288 0.013b
Age groups 2 and 3 (20–59 years) 0.350 0.014b 0.171 0.261b
a Compared by Pearson's correlation coefﬁcient analysis.
b Compared by Spearman's correlation coefﬁcient analysis.HPLC obtaining higher levels in urine samples of children with DS
than controls. The results obtained in the present work, including the
absence of correlation with age in DS and in controls, could be due to
cross-reaction of the commercial ELISA assay of JaICA which we used,
since urea and other substances contribute to the overestimation of
urinary 8-OHdG [18]. Therefore, these results should be taken with
caution and more studies are necessary in order to prove the
suitability of the ELISA assays used for the DNA damage assessment.
Since HPLC and other accurate techniques are currently limited in
population studies, novel spectrophotometric assays must be devel-
oped for the accurate determination of 8-OHdG.
3.2. Lipid peroxidation biomarkers (15-F2t-IsoP and TBARS)
Levels of lipid peroxidation biomarkers, 15-F2t-IsoP and TBARS,were
signiﬁcantly lower in DS than in controls for age group 3 (Table 2) and
both biomarkers correlated negatively with age in DS (Table 4 and
Fig. 1). Possible explanations to these results include that altered levels
of lipids and lipoproteins have been reported in DS [19,20]. Moreover,
carbonyl reductase 1, which gene (CBR1) is located on HSA21, protects
cells against lipid peroxidation [21] and is increased in DS individuals
[22]. However, our ﬁndings will require further investigation. On the
other hand, serum lipid resistance to oxidation has been found
signiﬁcantly higher in subjects with DS compared to controls [23] and
a concomitant increase in serumuric acidwasalsoobservedby the same
authors. In fact, Nyyssönen et al. [24] previously reported that ascorbate
and urate are the strongest determinants of plasma lipid peroxidation
resistance capacity. Although in a previous study of our research group
with a representative sample of the population used in this work, no
signiﬁcant increase in urinary uric acid levels was found in adults with
DS [4], Pallardó et al. [15] found increased levels of plasmatic uric acid in
a group of adolescents and adults (from 15 to 57 years) with DS. Thus,
we proposed as another possible explanation for our results that
negative correlations with age in DS, resulting in lower levels of both
biomarkers in DS than in controls for age group 3, could be the result of
an increased lipid resistance to oxidation in DS due to higher levels of
uric acid in blood. It has been recently reported, however, that plasma
lipid resistance to oxidation is not signiﬁcantly different in DS than in
non-Down subjects [25], although the correlation between uric acid and
plasma lipid resistance to oxidation has not been studied in this work
and further studies are clearly needed in this area.
Onemajor problemwith TBARS assay is the fact that it is performed
in numerous variations making comparisons of results between
laboratories difﬁcult. Moreover, much controversy has appeared in
studies concerning the speciﬁcity of TBARS towards composites other
than MDA. In fact, results in DS have indicated conﬂicting results. In a
similarmanner, commercially available ELISA assays against 15-F2t-IsoP
have not been tested for cross reactivity with most isoeicosanoids and
most of theirmetabolites so they are of uncertain quantitative reliability
in biological ﬂuids. Hence, although chromatographic techniques are
currently limited in population studies, they might provide better
results.
3.3. AGEs
High levels of AGEs occur in diabetes, cataracts and neurodegener-
ative diseases, such as Alzheimer disease, and all of them occur more
frequently in DS. It has been reported that oxidative stress is involved in
the accelerated formation of AGEs, which contribute to lower
retardation, reduced motor activity and decreased immune response,
meaning an accelerated aging process [26]. AGEs also depress
superoxide production by stimulated polymorphonuclear leukocytes
[27] and reduce SOD1 function. Therefore, AGEs couldplay an important
role in the oxidative status of DS patients.
In this study, we found signiﬁcant differences in urinary levels of
AGEs only between adolescents, from 15 to 19 years, with DS and
Fig. 1. Scatter plots of Cr, 8-OHdG/Cr, 15-F2t-IsoP/Cr, TBARS/Cr, AGEs/Cr, diTyr/Cr, H2O2/Cr and NOx/Cr vs. age in Down syndrome (DS) and controls (C) in the age groups 2 and 3
(from 20 to 59 years). Correlation lines are shown for DS (●, solid lines) and C (□, dashed lines). Individuals with DS receiving levothyroxine for hypothyroidism treatment are
identiﬁed in each graph as HT.
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the highest in this age group, Cr adjustment could bias the results.
Moreover, positive correlation between AGEs and agewas found only in
the control group (Table 4 and Fig. 1). By all of them, urinary AGEs
measured with the wide used ﬂuorescence assay of Yanagisawa et al.
[11] do not seem to be a suitable biomarker of oxidative stress in DS.
Pallardó et al. [15]measured glyoxal andmethylglyoxal levels in plasma
samples of DS patients and found higher levels of glyoxal in DS children
than in controls and no signiﬁcant differences in adolescents and adults
group. Opposite to glyoxal, plasma levels of methylglyoxal were
signiﬁcantly lower in adolescents and adults with DS than controls
and no signiﬁcant differences were reported in children. Thus, different
types of AGEs instead of the overall AGEs of a sample must be analyzed
with more speciﬁc techniques in DS patients, in a wider age range and
comparingplasmaandurine samples in order to clarify the usefulness of
a speciﬁc AGE as a biomarker of oxidative stress in DS.Table 4
Urinary levels of Cr and biomarkers of oxidative and nitrosative stress (8-OHdG, 15-F2t-IsoP
receiving levothyroxine for hypothyroidism and those without hypothyroidism diagnosed.
Urinary biomarker DS without hypothyroidism
n Mean±SD Range
Cr (mg/dL)
All ages (15–59 years) 54 138±65 27–298
Age group 1 (15–19 years) 20 133±57 45–276
Age group 2 (20–40 years) 22 155±66 50–298
Age group 3 (N40 years) 12 118±75 27–290
8-OHdG (ng/mg Cr)
All ages (15–59 years) 54 8.8±3.2 2.1–19.0
Age group 1 (15–19 years) 20 9.8±3.6 4.9–19.0
Age group 2 (20–40 years) 22 8.4±2.7 2.8–14.2
Age group 3 (N40 years) 12 8.0±3.1 2.1–12.7
15-F2t-IsoP (ng/mg Cr)
All ages (15–59 years) 54 0.95±0.56 0.22–2.98
Age group 1 (15–19 years) 20 1.13±0.65 0.26–2.98
Age group 2 (20–40 years) 22 0.98±0.45 0.25–1.87
Age group 3 (N40 years) 12 0.60±0.44 0.22–1.61
TBARS (μg/mg Cr)
All ages (15–59 years) 54 0.51±0.30 0.00–1.58
Age group 1 (15–19 years) 20 0.79±0.28 0.34–1.50
Age group 2 (20–40 years) 22 0.67±0.26 0.00–1.41
Age group 3 (N40 years) 12 0.65±0.40 0.08–1.58
AGEs (AFU/mg Cr)
All ages (15–59 years) 53 138±45 64–276
Age group 1 (15–19 years) 20 140±39 64–205
Age group 2 (20–40 years) 21 129±43 86–276
Age group 3 (N40 years) 12 154±55 99–270
DiTyr (AFU/mg Cr)
All ages (15–59 years) 53 721±508 165–3877
Age group 1 (15–19 years) 20 678±267 165–1208
Age group 2 (20–40 years) 21 740±756 259–3877
Age group 3 (N40 years) 12 759±232 349–1032
H2O2 (μg/mg Cr)
All ages (15–59 years) 48 0.66±0.63 0.00–3.14
Age group 1 (15–19 years) 20 0.82±0.71 0.22–3.14
Age group 2 (20–40 years) 20 0.51±0.40 0.00–1.39
Age group 3 (N40 years) 8 0.63±0.87 0.01–2.68
NOx (μg/mg Cr)
All ages (15–59 years) 52 77±81 19–503
Age group 1 (15–19 years) 20 117±118 28–503
Age group 2 (20–40 years) 21 51±24 19–101
Age group 3 (N40 years) 11 54±27 26–119
*Pb0.05 and **Pb0.01 (signiﬁcantly different) from the control group.
# Indicates P-value obtained in the comparisons between DS and controls by Mann–Whi3.4. DiTyr
DiTyr, also o,o′-dityrosine, is a ﬂuorescent molecule formed as a
result of normal posttranslational processes affecting speciﬁc struc-
tural proteins. Tyrosine is oxidized to diTyr in response to oxidative
stress by peroxidase-catalyzed mechanisms, being found in a number
of structural (lysozyme, calmodulin, myoglobin, and hemoglobin) and
non-structural proteins (insulin, RNase, and chymotrypsin) [28].
Moreover, tyrosine dimerization as well as nitration can be affected by
ONOO− (a powerful oxidant and nitrating agent), which can be
formed by the reaction between active NO metabolites and superox-
ide [29]. Therefore, diTyr could be considered as a biomarker of both
oxidative and nitrosative stress. In fact, it has been used as an
important biomarker for oxidatively modiﬁed proteins during UV and
γ-irradiation, aging, and exposure to oxygen free radicals, nitrogen
dioxide, peroxynitrite, and lipid hydroperoxides [30], and has been, TBARS, AGEs, diTyr, H2O2 and NOx) in patients with Down syndrome (DS) who were
The data are expressed as mean±standard deviation (SD) and ranges.
DS with treated hypothyroidism P#
n Mean±SD Range
24 102±51* 25–209 0.026
9 88±36* 25–164 0.038
11 112±56 34–209 0.086
4 108±72 35–207 0.903
23 9.0±4.1 3.0–24.5 0.781
9 8.0±1.8 5.7–11.5 0.220
11 9.7±5.7 3.0–24.5 0.819
3 9.5±1.4 8.1–10.9 0.386
24 0.90±0.60 0.19–2.78 0.458
9 1.16±0.68 0.46–2.78 0.962
11 0.83±0.56 0.19–2.35 0.169
4 0.50±0.19 0.30–0.73 0.903
24 0.76±0.44 0.14–2.36 0.622
9 0.86±0.64 0.14–2.36 0.944
11 0.80±0.26* 0.18–1.12 0.047
4 0.43±0.06 0.36–0.48 0.090
22 179±60** 93–324 0.003
9 152±37 116–234 0.696
10 175±53* 93–261 0.014
3 267±65* 196–324 0.022
22 969±538** 309–2473 0.008
9 1122±694* 557–2473 0.034
10 757±231* 309–1103 0.043
3 1214±670 520–1858 0.248
24 0.89±0.78 0.07–2.78 0.239
9 1.12±0.73 0.44–2.27 0.131
11 0.52±0.45 0.07–1.36 0.967
4 1.42±1.25 0.15–2.78 0.174
22 91±76 18–384 0.119
9 129±104 47–384 0.396
10 62±34 18–116 0.473
3 72±23 48–93 0.186
tney U-test.
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However, urinary levels of diTyr have been previously measured
neither in adolescents nor in adults with DS.
Our results showed signiﬁcantly higher levels of this biomarker in
DS patients than in controls for all age groups. Moreover, positive
correlationwith age was found in DS and in controls from 20 years old
(Table 4 and Fig. 1). Therefore, urinary diTyr could be considered as
biomarker of oxidative stress in adolescents and adults with DS and
the methodology for its determination is fast, simple and inexpensive
to perform.
3.5. H2O2
Urinary H2O2 was postulated to be a biomarker of oxidative stress
[31]. An excess of H2O2 is expected in DS patients due to over-
expression of SOD1, however urinary levels of this biomolecule have
been previously measured neither in adolescents nor in adults with
DS. Our results demonstrate that DS patients excreted more H2O2 in
urine than healthy controls aged from 15 to 40 years. However, we
found a large interindividual variation in urine H2O2 concentrations,
similar to what occurred in previous works [32], and it may bias the
results. Thus, a lack of correlation between H2O2 and age was found in
both DS and control groups (Table 4). Moreover, no signiﬁcant
differences in H2O2 levels have been found between both groups in
age group 3 (Table 2) probably due to the large biological variation,
which limits the usefulness of urinary H2O2 as a biomarker of
oxidative stress. In addition, it has been reported that drinking coffee,
exercise and salt loading affect H2O2 excretion [31]. Therefore, urinary
levels of H2O2 could be more determined bymetabolic and nutritional
inﬂuences than by changes in oxidative stress. In summary, our results
suggest that urinary H2O2 could be a suitable biomarker of oxidative
stress in DS, as it has also been proposed formalignancy [33], although
more studies are needed to explore the causes of its biological
variation.
3.6. Nitrite and nitrate (NOx)
Nitric oxide (NO) is a free radical gas which has been involved in a
wide range of physiological functions, including the modulation of
renal hemodynamics and excretory function [34]. Since NO rapidly
degrades to nitrite and nitrate (NOx), which are relatively slowly
excreted in urine, urinary levels of NOx were estimated as an index of
NO production. Although neurodegeneration in DS has been associ-
ated with aberrant expression of nitric oxide synthase 3 gene [35] and
nitrosative stress is linked to oxidative stress, biomarkers of
nitrosative stress have been little studied in DS.
In the present work we found higher levels of NOx in adolescents
and adults (from 15 to 40 years) with DS than in the age-matched
controls (Table 2). Besides, correlation of NOx with age was found
negative in DS from 14 years and positive in controls from 20 years
(Table 4). It has been reported that the tendency of urinary nitrate
levels to decrease with age in healthy children may be a reﬂection of
an age-related increase in glomerular ﬁltration rate [36]. Therefore,
glomerular ﬁltration rate could be impaired in DS as it is also shown
by the differences in Cr levels (Table 2), being urinary levels of NOx in
DS more inﬂuenced by urinary excretion than by oxidative status
contrary to what was observed in controls.
It must be taken into account that active NO metabolites can react
with superoxide to form peroxynitrite (ONOO−) a powerful oxidant
and nitrating agent. Tyrosine dimerization as well as nitration can be
affected by ONOO−, so the same oxidant could be responsible for the
accumulation of both 3-NO2-Tyr (3-nitrotyrosine) and diTyr [29].
Therefore, although NOx is a widely used biomarker of nitrosative
stress, 3-nitrotyrosine and diTyr would have been better indicators of
nitrosative damage.3.7. Analysis of hypothyroidism in DS
Hypothyroidism is common in adults with DS [37], being the
frequency of patients with DS treatedwith levothyroxine in the present
work of 31%. A decrease in free radical production is expected in
hypothyroidism due to themetabolic suppression brought about by the
decreased levels of thyroid hormone, however data are controversial
and several works reported increased oxidative stress in hypothyroid-
ism [38]. In the present study, patients with DS receiving levothyroxine
for hypothyroidism treatment showed increased levels of TBARS for age
group 2, increased levels of AGEs for age groups 2 and 3 and increased
levels of diTyr for age groups 1 and 2 than those without hypothyroid-
ism diagnosed (Table 4). However, impaired renal function has been
reported in patients with hypothyroidism [39]. It enhances serum Cr
levels because it reduces glomerular ﬁltration rate and increases
production of Cr. Our results showed lower levels of urinary Cr in DS
patients receiving levothyroxine than DS without hypothyroidism
diagnosed for age group 1, being levels in the rest of age groups slightly
decreased in DS patients receiving levothyroxine although without
signiﬁcant differences (Table 4). Therefore, renal impairment due to
hypothyroidism may bias the results in these patients.
Signs and symptoms of hypothyroidism can be difﬁcult to
discriminate from those found in the natural course of DS itself.
Moreover, untreated subclinical hypothyroidism is present in DS at
birth and persists throughout life [40]. Some abnormalities reported
in DS are related to thyroid function: 1) decreased levels of selenium
[41] which acts as an antioxidant protecting the thyrocyte from
peroxides, 2) an impairment in the activity of phenylalanine
hydroxylase [42], which converts the phenylalanine in tyrosine, and
3) overexpression of DYRK1A kinase [43], which could reduce the
availability of tyrosine. Hence, underlying factors may inﬂuence
thyroid function in DS. For all these reasons, it could be possible that a
group of DS patients without thyroid dysfunction diagnosed but
having untreated subclinical hypothyroidism are biasing the results,
in the present study and maybe in others researching clinical aspects
of DS.
3.8. Analysis of Cr adjustment
Renal impairment has been described in DS based on decreased Cr
clearance [44]. Interestingly, lower levels of urinary Cr have been
found in DS than in controls in all age groups (Table 2) and similar
results were obtained in DS vs. controls comparisons for all the
variables studied when patients with hypothyroidism were excluded.
Besides, negative correlation between Cr and age was found in DS
patients (Table 4 and Fig. 1), so a decline in urinary excretion with
aging could occur in DS patients. In fact, with increasing survival, an
increasing number of DS patients with renal disease are being
reported [45]. In summary, Cr used for standardized urinary levels
of biomarkers studied may bias the results, as it has been discussed
above for all the biomarkers studied, and it could be due to
hypothyroidism in DS.
3.9. Post-hoc comparisons between age groups
Post-hoc comparisons between age groups for both DS and control
groups are shown in Table 2. Signiﬁcant differences were found in
urinary AGEs between age groups 2 and 3 (P=0.032) in controls. In
DS, signiﬁcant differences were found in urinary 15-F2t-IsoP between
age groups 1 and 3 (P=0.004) and between age groups 2 and 3
(P=0.042), and also in urinary NOx between age groups 1 and 2
(P=0.005) and between age groups 1 and 3 (P=0.035). These results
are in accordance with correlation results. However, we found some
correlations between urinary parameters with age, but no signiﬁcant
differences were found in post-hoc comparisons between age groups
in both DS and control groups. Further studies must be performed
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nitrosative stress can be established.
3.10. Future approaches
Previous studies addressing biomarkers of oxidative stress in DS
have shown conﬂicting results. Methodological aspects are not usually
taken into account in the approach to discussion. Moreover, since
oxidative conditions have been suggested to be of importance in
developmental and maturational processes, biomarkers of oxidative
stress may need to be differently interpreted in childhood and
adulthood. Nonetheless, we can found several works studying them in
disease states, including DS, in which age groups are formed by both
children and adolescents or even children and adults, sodiscrepancies in
results are frequently found.
On theother hand, adultswithDS over40 years are under higher risk
for dementia. However, the diagnosis of Alzheimer disease in people
with DS is far from an easy task and oxidative damagemay increase as a
consequence of this disease process in addition to aging, biasing the
results. Improvements in this area are required before the causes of
increased oxidative stress in senescent DS subjects can be well
established.
DS subjects have a high prevalence to have or develop hypothyroid-
ism. In our study, we found clinically important changes in hypothyroid
DS patients taking levothyroxine compared to those without hypothy-
roidism diagnosed, suggesting that medical treatment does not
normalize alterations caused by thyroid dysfunction in these subjects.
Hence, thyroid hormones levels must be assessed together with
oxidative stress biomarkers in future works, even more when DS
subjects can suffer from untreated subclinical hypothyroidism.
In our study,we obtained P-values higher than the conventional cut-
off of 0.05 but close to this value in several of the between-group
comparisons. Such data are suggestive of an effect. Thus, there could be
some results of clinical relevance, although no statistical differences
have been obtained (type II error). Moreover, high variability in urinary
levels of all biomarkers was obtained. Sample size and variability are
important primarily because of its effect on statistical power. Hence,
statistical powermay be limited not only in subgroup analyses, but also
by the statistical variability. Therefore, to assess urinary biomarkers of
oxidative/nitrosative stress in a large number of adolescent and/or adult
individuals with DS must be a major goal in future works.
Individuals with DS could suffer from renal impairment, leading to
a diminished excretion of metabolites such as oxidative/nitrosative
stress biomarkers. Therefore, a comparative study assessing a
comprehensive set of these biomarkers in both urine and plasma or
serum samples must be performed in DS to clarify this hypothesis.
Finally, potential biasing factors, such as dietary or exercise habits,
exposure to pollutants, etc., must be considered in future works
studying oxidative/nitrosative stress biomarkers in DS. In fact, in our
study most individuals with DS practiced moderate physical activity
weekly. Therefore, improvements in life patterns of DS individuals
could contribute to reduce oxidative stress, biasing the results.
In summary, similar studies in a larger number of DS subjects, in
which thyroid dysfunctions have been described and performed in
various biologicalmatrices, such as serum, plasma and urine, andwhere
potential biasing factors, such as dietary or exercise habits, exposure to
pollutants, etc., are considered,wouldhelp to clarify the role of oxidative
stress in DS phenotype and subsequently devising intervention
strategies which improve the quality of life of these patients.
4. Conclusion
This work shows that AGEs, diTyr, H2O2 and NOx could be used as
biomarkers of oxidative/nitrosative stress in urine samples of adoles-
cents and adults with DS in contrast to 8-OHdG, 15-F2t-IsoP and TBARS,
at least with the methods described in the present study. However,intraindividual variability was high for most of the variables studied,
mainly in DS patients. Besides, the present work shows evidence of a
probable renal impairment inDSandCradjustmentmaybias the results,
particularly in hypothyroid patients.
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